Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiac Event Risk Clear all
Completed No phase listed Observational Accepts healthy volunteers

A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World

NCT04276441
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Heart healthy Engagement Program with the Apple Watch Series 5 or later, Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
Device
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
65 Years and older
Enrollment
34,244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 25, 2026, 10:43 AM EDT
Active, not recruiting Phase 4 Interventional

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

NCT05284747
View directory record Official record
Conditions
Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions
Evolocumab, Routine Lipid Management
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
6,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 25, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

NCT02924727
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 25, 2026, 10:43 AM EDT
Completed Not applicable Interventional Results available

Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications

NCT02694185
View directory record Official record
Conditions
Myocardial Ischemia, Rheumatic Diseases
Interventions
Caplan IVR
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 95 Years
Enrollment
5,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 25, 2026, 10:43 AM EDT
Completed Phase 4 Interventional Results available

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

NCT02415400
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 95 Years
Enrollment
4,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 25, 2026, 10:43 AM EDT
Recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 25, 2026, 10:43 AM EDT
Terminated Phase 3 Interventional

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

NCT00243178
View directory record Official record
Conditions
Atrial Fibrillation, Vascular Risk
Interventions
clopidogrel (SR25990C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
6,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 19, 2009 · Synced Oct 25, 2026, 10:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

How Clinical and Personal Information Shape Physicians' Risk Judgments

NCT07162376
View directory record Official record
Conditions
Major Adverse Cardiac Event (MACE)
Interventions
Personal Information Disclosure
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 25, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

NCT00249873
View directory record Official record
Conditions
Atrial Fibrillation, Vascular Risk
Interventions
clopidogrel (SR25990C), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 25, 2026, 10:43 AM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975376
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
545
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 25, 2026, 10:43 AM EDT
Not listed No phase listed Observational

Anticoagulant and Antiarrhythmic Management Based on Continuous Rhythm Monitoring

NCT04038944
View directory record Official record
Conditions
New Onset Atrial Fibrillation
Interventions
Not listed
Lead sponsor
St. Francis Hospital, New York
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 25, 2026, 10:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aspirin Responsiveness in Women at Risk for Cardiac Events

NCT00818337
View directory record Official record
Conditions
Heart Disease
Interventions
Aspirin
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 25, 2026, 10:43 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

NCT07448038
View directory record Official record
Conditions
Atherosclerosis
Interventions
Selnoflast, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
24
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 10:43 AM EDT
Completed No phase listed Observational

Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy

NCT00753233
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 21 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

NCT00501059
View directory record Official record
Conditions
Moderate Risk of CVD
Interventions
Aspirin (Acetylsalicylic acid, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
55 Years and older
Enrollment
12,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
73
States / cities
Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 25, 2026, 10:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
242
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 188 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 10:43 AM EDT
Not listed No phase listed Observational

Heart Failure Event Advance Detection Trial

NCT04223271
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Decompensated Heart Failure
Interventions
Indicor
Diagnostic Test
Lead sponsor
Vixiar Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 25, 2026, 10:43 AM EDT
Recruiting Not applicable Interventional

Digital Monitoring for Patients Post Coronary Interventions to Reduce Risk for Recurrent Adverse Cardiovascular Events

NCT06114615
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
LiveCare, Text Messages, Conventional Care
Device · Behavioral · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 25, 2026, 10:43 AM EDT
Completed No phase listed Observational

Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)

NCT02332070
View directory record Official record
Conditions
Acute Kidney Injury, Renal Insufficiency
Interventions
cardiac surgery
Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
Not listed
Enrollment
965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 25, 2026, 10:43 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

NCT06112418
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Interventions
The Cleerly CAD Staging System
Device
Lead sponsor
Cleerly, Inc.
Industry
Eligibility
55 Years and older
Enrollment
7,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
125
States / cities
Chandler, Arizona • Scottsdale, Arizona • Sun City, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 10:43 AM EDT
Withdrawn No phase listed Observational

T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events

NCT01796743
View directory record Official record
Conditions
Myocardial Infarction, Acute
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 25, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

NCT01877915
View directory record Official record
Conditions
Heart Failure, Coronary Artery Disease
Interventions
Rivaroxaban, Placebo, Standard of care for heart failure and coronary artery disease
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 95 Years
Enrollment
5,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
115
States / cities
Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 25, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 25, 2026, 10:43 AM EDT
Not listed No phase listed Observational

Cardiovascular Outcomes in the VA's Rheumatoid Arthritis(VARA) Population

NCT00431405
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease, Coronary Disease
Interventions
Not listed
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2007 · Synced Oct 25, 2026, 10:43 AM EDT